var data={"title":"Folic acid: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Folic acid: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6228?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=folic-acid-drug-information\" class=\"drug drug_general\">see &quot;Folic acid: Drug information&quot;</a> and <a href=\"topic.htm?path=folic-acid-patient-drug-information\" class=\"drug drug_patient\">see &quot;Folic acid: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6813283\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>FA-8 [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173692\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Folic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058799\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Nutritional Supplement</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vitamin, Water Soluble</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442542\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Enteral daily recommendations; adequate intake</b> (Vanek, 2012): Oral:  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature neonates: 25-50 mcg/kg/day  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Full-term neonates: 65 mcg/day </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parenteral nutrition, maintenance requirement of folic acid</b> (Vanek, 2012): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature neonates: 56 mcg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Full-term neonates: 140 mcg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058794\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=folic-acid-drug-information\" class=\"drug drug_general\">see &quot;Folic acid: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\"> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Adequate intake (AI):</b> Oral: <b>Note:</b> Dosing presented as dietary folate equivalents (DFE) to adjust for ~50% decreased bioavailability of food folate compared with that of folic acid supplement.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1-6 months: 65 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">7-12 months: 80 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommended daily allowance (RDA):</b> Oral: <b>Note:</b> Dosing presented as dietary folate equivalents (DFE) to adjust for ~50% decreased bioavailability of food folate compared with that of folic acid supplement.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1-3 years: 150 mcg/day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">4-8 years: 200 mcg/day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">9-13 years: 300 mcg/day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;14 years: 400 mcg/day </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anemia (folic acid deficiency); treatment:</b> Oral, IM, IV, SubQ: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 0.1 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;4 years: Up to 0.3 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;4 years and Adolescents: 0.4 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Parenteral nutrition, maintenance requirement of folic acid</b> (Vanek, 2012): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 56 mcg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &le;13 years: 140 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;14 years: 400 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gingival hyperplasia due to phenytoin, prevention:</b> Limited data available: Oral: Children &ge;6 years and Adolescents: 0.5 mg/day was used in a double-blind, randomized, placebo-controlled trial of 120 pediatric patients (treatment arm, n=62; age range: 6-15 years) who were started on phenytoin therapy within the last month for a seizure disorder; results showed a statistically significant difference in development of hyperplasia (treatment arm: 21% vs placebo: 88%); severity of cases less in treatment arm than placebo; study duration: 6 months (Arya, 2011)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Recommended daily allowance (RDA):</b> Expressed as dietary folate equivalents: Oral: 400 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pregnancy: 600 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lactation: 500 mcg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anemia (folic acid deficiency); treatment:</b> Oral, IM, IV, SubQ: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Nonpregnant and nonlactating adults: 0.4 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pregnant and lactating women: 0.8 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of neural tube defects:</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Females of childbearing potential: 400-800 mcg/day (USPSTF, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Females at high-risk or with family history of neural tube defects: 4 mg/day (ACOG, 2003) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173671\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">FA-8: 0.8 mg [dye free, sugar free, yeast free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sodium folate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 mcg, 800 mcg, 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">FA-8: 800 mcg [dye free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 400 mcg, 800 mcg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173657\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058803\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: May be administered without regard to meals </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM, SubQ: May administer undiluted deep IM or SubQ</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: May administer doses &le;5 mg undiluted over &ge;1 minute <b>or</b> may further dilute  and infuse over 30 minutes. May also be given as an infusion when added to IV maintenance solutions. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25211359\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058802\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of megaloblastic and macrocytic anemias due to folate deficiency (FDA approved in all ages); has also been used as a dietary supplement to prevent neural tube defects and prevention of gingival hyperplasia due to phenytoin </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173740\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Folic acid may be confused with folinic acid (leucovorin calcium)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173738\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing (slight)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Malaise (general)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173679\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to folic acid or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173661\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anemia: Monotherapy: Not appropriate for monotherapy with pernicious, aplastic, or normocytic anemias when anemia is present with vitamin B<sub>12 </sub> deficiency. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pernicious anemia: Doses &gt;0.1 mg/day may obscure pernicious anemia with continuing irreversible nerve damage progression.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register, 2002). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Resistance to treatment: May occur with depressed hematopoiesis, alcoholism, and deficiencies of other vitamins. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299358\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173665\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13322&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Folic Acid may decrease the serum concentration of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Green Tea: May decrease the serum concentration of Folic Acid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: Folic Acid may decrease the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Folic Acid may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: Folic Acid may decrease the serum concentration of Primidone. Additionally, folic acid may decrease concentrations of active metabolites of primidone (e.g., phenobarbital). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltitrexed: Folic Acid may diminish the therapeutic effect of Raltitrexed. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SulfaSALAzine: May decrease the serum concentration of Folic Acid.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173668\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">A (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173683\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Water soluble vitamins cross the placenta. Folate requirements increase during pregnancy. Folate supplementation during the periconceptual period decreases the risk of neural tube defects (ACOG 2003; USPSTF 2009). Folate supplementation (doses larger than the RDA) is recommended for women who may become pregnant (IOM 1998). Folic acid is also indicated for the treatment of anemias due to folate deficiency in pregnant women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058798\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058801\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Total folate: Normal: 5-15 ng/mL; folate deficiency: &lt;5 ng/mL; megaloblastic anemia: &lt;2 ng/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173660\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Folic acid is necessary for formation of a number of coenzymes in many metabolic systems, particularly for purine and pyrimidine synthesis; required for nucleoprotein synthesis and maintenance in erythropoiesis; stimulates WBC and platelet production in folate deficiency anemia. Folic acid enhances the metabolism of formic acid, the toxic metabolite of methanol, to nontoxic metabolites (off-label use).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173678\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Peak effect: Oral: 0.5-1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Proximal part of small intestine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: Folic acid supplement: ~100%; In presence of food: 85%; Dietary folate: 50% (IOM 1998) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058809\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Dietary folate equivalents (DFE)  is used to adjust for ~50% decreased bioavailability of food folate compared with that of folic acid supplement: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1 mcg DFE = 0.6 mcg folic acid from fortified food or as a supplement taken with meals, or</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1 mcg DFE of food folate = 0.5 mcg of a supplement taken on an empty stomach</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">As of January 1998, the FDA has required manufacturers of enriched flour, bread, corn meal, pasta, rice, and other grain products to add folic acid to their products. The intent is to help decrease the risk of neural tube defects by increasing folic acid intake. Other foods which contain folic acid include dark green leafy vegetables, citrus fruits and juices, and lentils.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173677\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 1 mg/mL folic acid oral solution may be made with tablets. Heat 90 mL of purified water almost to boiling. Dissolve parabens (methylparaben 200 mg and propylparaben 20 mg) in the heated water; cool to room temperature. Crush one-hundred 1 mg tablets, then dissolve folic acid in the solution. Adjust pH to 8-8.5 with sodium hydroxide 10%; add sufficient quantity of purified water to make 100 mL; mix well. Stable for 30 days at room temperature (Allen, 2007).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 0.05 mg/mL folic acid oral solution may be prepared using the injectable formulation (5 mg/mL). Mix 1 mL of injectable folic acid with 90 mL of purified water. Adjust pH to 8-8.5 with sodium hydroxide 10%; add sufficient quantity of purified water to make 100 mL; mix well. Stable for 30 days at room temperature (Nahata, 2004).</p>\n    <div class=\"reference\">Allen LV Jr, &quot;Folic Acid 1-mg/mL Oral Liquid,&quot; <i>Int J Pharm Compound</i>, 2007, 11(3):244.</div>\r\n\n    <div class=\"reference\">Nahata MC, Pai VB, and Hipple TF, <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173682\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (FA-8 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.8 mg (100): $3.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Folic Acid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $7.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $8.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Folic Acid Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (10 mL): $54.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (FA-8 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mcg (100): $3.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Folic Acid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (100): $35.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mcg (100): $2.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mcg (100): $3.35</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173685\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>A.F. Valdecasas (MX);</li>\n      <li>Acfol (ES, PT);</li>\n      <li>Acide Folique CCD (FR);</li>\n      <li>Acido Folico (AR, CO, EC, PE);</li>\n      <li>Acido Folico Fada (AR);</li>\n      <li>Acifol (AR);</li>\n      <li>Anemolat (ID);</li>\n      <li>Apo-Folic (NZ);</li>\n      <li>Bio-Folic (BE);</li>\n      <li>Clonfolic (IE);</li>\n      <li>Conacid (AR);</li>\n      <li>Elvefocal (AR);</li>\n      <li>Endofolin (BR);</li>\n      <li>Enhansid (PH);</li>\n      <li>Feri (PH);</li>\n      <li>Filicine (GR, MT);</li>\n      <li>Fionat (ID);</li>\n      <li>Folac (BD);</li>\n      <li>Folacid (PL);</li>\n      <li>Folacin (BR, HR, RU, SE, TW);</li>\n      <li>Folart (PH);</li>\n      <li>Folate (BD);</li>\n      <li>Folavit (BE, LU);</li>\n      <li>Folbiol (TR);</li>\n      <li>Folee-1 (LK);</li>\n      <li>Foli 5 (IL);</li>\n      <li>Foliage (PH);</li>\n      <li>Foliamin (HK, JP, TH);</li>\n      <li>Folic Acid DHA (MY);</li>\n      <li>Folic Acid Pharm Ecologist (AR);</li>\n      <li>Folicare (BH);</li>\n      <li>Folicid (KR);</li>\n      <li>Folicil (CY, HK, MT, PT);</li>\n      <li>Folicum (AE, BH, KW, QA, SA);</li>\n      <li>Folimax (PH);</li>\n      <li>Folimen (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Folimet (DK);</li>\n      <li>Folin (BR);</li>\n      <li>Folina (IT, MY);</li>\n      <li>Folinsyre &rdquo;Dak&rdquo; (DK);</li>\n      <li>Foliphar (BE);</li>\n      <li>Folitab (QA);</li>\n      <li>Folivit (TH);</li>\n      <li>Folivita (SA);</li>\n      <li>Folivital (MX);</li>\n      <li>Foloicare (AE);</li>\n      <li>Folsan (AT, HR);</li>\n      <li>Folsyre (NO);</li>\n      <li>Folverlan (DE);</li>\n      <li>Folvite (AE, BB, BH, BM, BS, BZ, CH, CY, EG, FI, GY, IL, IQ, IR, JM, JO, KW, LB, LY, NL, OM, SA, SR, SY, TT, YE);</li>\n      <li>Gravi-Fol (DE);</li>\n      <li>Gravida (BE);</li>\n      <li>Huma-Folacid (HU);</li>\n      <li>Ingafol (IN, LK);</li>\n      <li>Lexpec (GB);</li>\n      <li>Megafol (AU);</li>\n      <li>Mithra Folic (BE);</li>\n      <li>Nufolic (ID);</li>\n      <li>Prinac AC (MX);</li>\n      <li>Quatro (ID);</li>\n      <li>RubieFol (DE);</li>\n      <li>Tecnovorin (BR);</li>\n      <li>Tesha-1 (LK);</li>\n      <li>Tonixan (PY);</li>\n      <li>Travital Folic Acid (BE);</li>\n      <li>Tyfol (UA);</li>\n      <li>Vifolin (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins, &quot;Clinical Management Guidelines for Obstetrician-Gynecologists. Number 44, July 2003 (Replaces Committee Opinion Number 252, March 2001),&quot; <i>Obstet Gynecol</i>, 2003, 102(1):203-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/folic-acid-pediatric-drug-information/abstract-text/12850637/pubmed\" target=\"_blank\" id=\"12850637\">12850637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/folic-acid-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/folic-acid-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arya R, Gulati S, Kabra M, et al, &quot;Folic Acid Supplementation Prevents Phenytoin-Induced Gingival Overgrowth in Children,&quot; <i>Neurology</i>, 2011, 76(15):1338-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/folic-acid-pediatric-drug-information/abstract-text/21482950/pubmed\" target=\"_blank\" id=\"21482950\">21482950</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/folic-acid-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Department  Health &amp; Human Services, Food Drug Administration, &quot;Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,&quot;  <i>Federal Register</i>, 2000, 65(17):4103-11.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B</i><sub>12</sub><i>, Pantothenic Acid, Biotin and Choline</i>, Washington, DC: National Academy Press, 1998.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    U.S. Preventive Services Task Force (USPSTF), &quot;Folic Acid for the Prevention of Neural Tube Defects: U.S. Preventive Services Task Force Recommendation Statement,&quot; <i>Ann Intern Med</i>, 2009, 150(9):626-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/folic-acid-pediatric-drug-information/abstract-text/19414842/pubmed\" target=\"_blank\" id=\"19414842\">19414842</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanek VW, Borum P, Buchman A, et al, &quot;A.S.P.E.N. Position Paper: Recommendations for Changes in Commercially Available Parenteral Multivitamin and Multi-trace Element Products,&quot; <i>Nutr Clin Pract</i>, 2012, 27(4):440-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/folic-acid-pediatric-drug-information/abstract-text/22730042/pubmed\" target=\"_blank\" id=\"22730042\">22730042</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13322 Version 168.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F6813283\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F173692\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1058799\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442542\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1058794\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F173671\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F173657\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1058803\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F25211359\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1058802\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F173740\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F173738\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F173679\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F173661\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299358\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F173665\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F173668\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F173683\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1058798\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1058801\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F173660\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F173678\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1058809\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F173677\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F173682\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F173685\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13322|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=folic-acid-drug-information\" class=\"drug drug_general\">Folic acid: Drug information</a></li><li><a href=\"topic.htm?path=folic-acid-patient-drug-information\" class=\"drug drug_patient\">Folic acid: Patient drug information</a></li></ul></div></div>","javascript":null}